Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 3084859, 17 pages
https://doi.org/10.1155/2017/3084859
Review Article

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews

1Laboratory of Molecular and Translational Psychiatry, Department of Neuroscience, School of Medicine, University “Federico II”, Naples, Italy
2New York State Psychiatric Institute, Columbia University, New York, NY, USA
3National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4, Teramo, Italy
4Department of Clinical Neurosciences, Hermanas Hospitalarias, Villa San Benedetto Menni Hospital, FoRiPsi, Albese con Cassano, 22032 Como, Italy
5Department of Psychiatry and Neuropsychology, Maastricht University, 6200 MD Maastricht, Netherlands
6Department of Psychiatry and Behavioral Sciences, Leonard Miller School of Medicine, Miami University, Miami, FL 33136, USA
7Department of Neurosciences, University of Padua, Padua, Italy
8Institute for Clinical Research and Education in Medicine (IREM), Padua, Italy
9Department of Medicine (DIMED), University of Padua, Padua, Italy
10School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts, UK
11Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, CE, Brazil

Correspondence should be addressed to Michele Fornaro; moc.liamg@oranrof.ttod

Received 31 October 2016; Revised 1 February 2017; Accepted 21 February 2017; Published 9 May 2017

Academic Editor: Chi-Un Pae

Copyright © 2017 Michele Fornaro et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. APA, Diagnostic and Statistical Manual for Mental Disorders, APA, Washington, DC, USA, 4th edition, 1994.
  2. American Psychiatric Association, “Bipolar and related disorders,” in Diagnostic and Statistical Manual for Mental Disorders, p. 123, American Psychiatric Association, Washington, DC, USA, 2013. View at Google Scholar
  3. H. A. Swartz and M. E. Thase, “Pharmacotherapy for the treatment of acute bipolar II depression: current evidence,” The Journal of Clinical Psychiatry, vol. 72, no. 3, pp. 356–366, 2011. View at Publisher · View at Google Scholar
  4. K. N. Fountoulakis, Bipolar Disorder: An Evidence-Based Guide to Manic Depression, Springer, New York, NY, USA, 2014.
  5. C. F. Baldassano, A. Hosey, and J. Coello, “Bipolar depression: an evidence-based approach,” Current Psychiatry Reports, vol. 13, no. 6, pp. 483–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Zohar, S. Stahl, H.-J. Moller et al., “A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature,” European Neuropsychopharmacology, vol. 25, no. 12, pp. 2318–2325, 2015. View at Publisher · View at Google Scholar · View at Scopus
  7. B. Stubbs, D. Vancampfort, M. Solmi, N. Veronese, and M. Fornaro, “How common is bipolar disorder in general primary care attendees? A systematic review and meta-analysis investigating prevalence determined according to structured clinical assessments,” Australian and New Zealand Journal of Psychiatry, vol. 50, no. 7, pp. 631–639, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. K. N. Fountoulakis, X. Gonda, E. Vieta, and Z. Rihmer, “Class effect of pharmacotherapy in bipolar disorder: fact or misbelief?” Annals of General Psychiatry, vol. 10, article 8, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. K. Rybakowski, “Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective,” Journal of Affective Disorders, vol. 136, no. 1-2, pp. e13–e19, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Fornaro, M. Martino, C. De Pasquale, and D. Moussaoui, “The argument of antidepressant drugs in the treatment of bipolar depression: mixed evidence or mixed states?” Expert Opinion on Pharmacotherapy, vol. 13, no. 14, pp. 2037–2051, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. I. Pacchiarotti, D. J. Bond, R. J. Baldessarini et al., “The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders,” The American Journal of Psychiatry, vol. 170, no. 11, pp. 1249–1262, 2013. View at Publisher · View at Google Scholar
  12. M. Sagud, A. Mihaljevic-Peles, D. Begic et al., “Antipsychotics as antidepressants: what is the mechanism?” Psychiatria Danubina, vol. 23, no. 3, pp. 302–307, 2011. View at Google Scholar
  13. B. M. Wright, E. H. Eiland, and R. Lorenz, “Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature,” Pharmacotherapy, vol. 33, no. 3, pp. 344–359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Bjørklund, H. T. Horsdal, O. Mors, S. D. Østergaard, and C. Gasse, “Trends in the psychopharmacological treatment of bipolar disorder: a nationwide register-based study,” Acta Neuropsychiatrica, vol. 28, no. 2, pp. 75–84, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Dodd, B. S. Fernandes, and O. M. Dean, “Future directions for pharmacotherapies for treatment-resistant bipolar disorder,” Current Neuropharmacology, vol. 13, no. 5, pp. 656–662, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. R. M. Post, “Treatment of bipolar depression: evolving recommendations,” Psychiatric Clinics of North America, vol. 39, no. 1, pp. 11–33, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Fornaro, D. De Berardis, A. S. Koshy et al., “Prevalence and clinical features associated with bipolar disorder polypharmacy: a systematic review,” Neuropsychiatric Disease and Treatment, vol. 12, pp. 719–735, 2016. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Fornaro, B. Stubbs, D. De Berardis et al., “Atypical antipsychotics in the treatment of acute bipolar depression with mixed features: a systematic review and exploratory meta-analysis of placebo-controlled clinical trials,” International Journal of Molecular Sciences, vol. 17, no. 2, article 241, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Shah, P. Yadav, M. Chaudhari, J. Rai, and N. Kantharia, “Bipolar disorder: a review of current U.S. Food and Drug Administration approved pharmacotherapy,” International Journal of Basic and Clinical Pharmacology, pp. 623–631, 2015. View at Publisher · View at Google Scholar
  20. R. S. McIntyre, D. S. Cha, R. D. Kim, and R. B. Mansur, “A review of FDA-approved treatment options in bipolar depression,” CNS Spectrums, vol. 18, supplement 1, pp. 4–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. R. S. McIntyre, D. S. Cha, R. D. Kim, and R. B. Mansur, “A review of FDA-approved treatment options in bipolar depression,” CNS Spectrums, vol. 18, supplement 1, pp. 1–21, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Bawa and J. R. Scarff, “Lurasidone: a new treatment option for bipolar depression—a review,” Innovations in Clinical Neuroscience, vol. 12, no. 1-2, pp. 21–23, 2015. View at Google Scholar · View at Scopus
  23. A. Loebel, J. Cucchiaro, R. Silva et al., “Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study,” American Journal of Psychiatry, vol. 171, no. 2, pp. 160–168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Loebel, J. Cucchiaro, R. Silva et al., “Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study,” American Journal of Psychiatry, vol. 171, no. 2, pp. 169–177, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Suppes, H. Kroger, A. Pikalov, and A. Loebel, “Lurasidone adjunctive with lithium or valproate for bipolar depression: a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts,” Journal of Psychiatric Research, vol. 78, pp. 86–93, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Dols, D. Rhebergen, A. Beekman, R. Kupka, M. Sajatovic, and M. L. Stek, “Psychiatric and medical comorbidities: results from a bipolar elderly cohort study,” American Journal of Geriatric Psychiatry, vol. 22, no. 11, pp. 1066–1074, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Ketter, K. Sarma, and R. Silva, “Lurasidone in bipolar I depression: a 24-week, open-label extension study [abstract no. 17 plus poster],” in Proceedings of the Annual Meeting of the American Society of Clinical Psychopharmacology, Hollywood, Fla, USA, 2014.
  28. T. A. Ketter, K. Sarma, R. Silva, H. Kroger, J. Cucchiaro, and A. Loebel, “Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study,” Depression and Anxiety, vol. 33, no. 5, pp. 424–434, 2016. View at Publisher · View at Google Scholar · View at Scopus
  29. C. B. Schaffer, L. C. Schaffer, T. E. Nordahl, N. M. Stark, and C. E. Gohring, “An open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder,” Journal of Clinical Psychopharmacology, vol. 36, no. 1, pp. 88–89, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. I. R. McGrane and M. Stuhec, “Comment on an open trial of lurasidone as an acute and maintenance adjunctive treatment for outpatients with treatment-resistant bipolar disorder,” Journal of Clinical Psychopharmacology, vol. 36, no. 5, pp. 520–521, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Citrome, T. A. Ketter, J. Cucchiaro, and A. Loebel, “Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed,” Journal of Affective Disorders, vol. 155, no. 1, pp. 20–27, 2014. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Citrome, “Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it,” Journal of Clinical Psychiatry, vol. 72, no. 3, pp. 412–413, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. L. Alphs, J. Berwaerts, and I. Turkoz, “Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response,” European Neuropsychopharmacology, vol. 23, no. 11, pp. 1597–1599, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. R. Ganann, D. Ciliska, and H. Thomas, “Expediting systematic reviews: methods and implications of rapid reviews,” Implementation Science, vol. 5, no. 1, article 56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. H. Bastian, P. Glasziou, and I. Chalmers, “Seventy-five trials and eleven systematic reviews a day: how will we ever keep up?” PLoS Medicine, vol. 7, no. 9, Article ID e1000326, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Moher, J. Tetzlaff, A. C. Tricco, M. Sampson, and D. G. Altman, “Epidemiology and reporting characteristics of systematic reviews,” PLoS Medicine, vol. 4, no. 3, article e78, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. T. D. Pigott, Advances in Meta-Analysis, Statistics for Social and Behavioral Sciences, Springer, New York, NY, USA, 2012. View at Publisher · View at Google Scholar · View at MathSciNet
  38. R. M. Turner, S. M. Bird, and J. P. T. Higgins, “The impact of study size on meta-analyses: examination of underpowered studies in cochrane reviews,” PLoS ONE, vol. 8, no. 3, Article ID e59202, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Smith, D. Devane, C. M. Begley, and M. Clarke, “Methodology in conducting a systematic review of systematic reviews of healthcare interventions,” BMC Medical Research Methodology, vol. 11, article 15, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. M. Tsagris and K. C. Fragkos, “Umbrella reviews, overviews of reviews, and meta-epidemiologic studies: similarities and differences,” in Umbrella Reviews, pp. 43–54, Springer International Publishing, Cham, Switzerland, 2016. View at Publisher · View at Google Scholar
  41. D. Moher, L. Shamseer, M. Clarke et al., “Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement,” Systematic Reviews, vol. 4, no. 1, p. 1, 2015. View at Google Scholar
  42. B. J. Shea, J. M. Grimshaw, G. A. Wells et al., “Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews,” BMC Medical Research Methodology, vol. 7, no. 1, article 10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. B. J. Shea, C. Hamel, G. A. Wells et al., “AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews,” Journal of Clinical Epidemiology, vol. 62, no. 10, pp. 1013–1020, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Kung, F. Chiappelli, O. O. Cajulis et al., “From systematic reviews to clinical recommendations for evidence-based health care: validation of revised assessment of multiple systematic reviews (R-AMSTAR) for grading of clinical relevance,” The Open Dentistry Journal, vol. 4, no. 1, 2010. View at Google Scholar
  45. K. Hemming, T. Pinkney, K. Futaba, M. Pennant, D. G. Morton, and R. J. Lilford, “A systematic review of systematic reviews and panoramic meta-analysis: staples versus sutures for surgical procedures,” PLoS ONE, vol. 8, no. 10, Article ID e75132, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. M. De Hert, W. Yu, J. Detraux, K. Sweers, R. Van Winkel, and C. U. Correll, “Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder,” CNS Drugs, vol. 26, no. 9, pp. 733–759, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. F. I. Tarazi and S. M. Stahl, “Iloperidone, asenapine and lurasidone: a primer on their current status,” Expert Opinion on Pharmacotherapy, vol. 13, no. 13, pp. 1911–1922, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Gao, C. Yuan, R. Wu et al., “Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat,” Neuroscience Bulletin, vol. 31, no. 5, pp. 572–588, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Sanford and S. Dhillon, “Lurasidone: a review of its use in adult patients with bipolar I depression,” CNS Drugs, vol. 29, no. 3, pp. 253–263, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. R. R. Jaeschke, M. Sowa-Kućma, P. Pańczyszyn-Trzewik, P. Misztak, K. Styczeń, and W. Datka, “Lurasidone: the 2016 update on the pharmacology, efficacy and safety profile,” Pharmacological Reports, vol. 68, no. 4, pp. 748–755, 2016. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. S. Woo, H. R. Wang, and W.-M. Bahk, “Lurasidone as a potential therapy for bipolar disorder,” Neuropsychiatric Disease and Treatment, vol. 9, pp. 1521–1529, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. L. J. Findlay, P. El-Mallakh, and R. S. El-Mallakh, “Management of bipolar I depression: clinical utility of lurasidone,” Therapeutics and Clinical Risk Management, vol. 11, pp. 75–81, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Angst, “The course of affective disorders,” Archiv für Psychiatrie und Nervenkrankheiten, vol. 226, no. 1, pp. 65–73, 1978. View at Publisher · View at Google Scholar
  54. J. P. T. Higgins, D. G. Altman, P. C. Gøtzsche et al., “The Cochrane Collaboration's tool for assessing risk of bias in randomised trials,” British Medical Journal, vol. 343, no. 7829, Article ID d5928, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Pieper, R. B. Buechter, L. Li, B. Prediger, and M. Eikermann, “Systematic review found AMSTAR, but not R(evised)-AMSTAR, to have good measurement properties,” Journal of Clinical Epidemiology, vol. 68, no. 5, pp. 574–583, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. C. M. Faggion, “Critical appraisal of AMSTAR: challenges, limitations, and potential solutions from the perspective of an assessor,” BMC Medical Research Methodology, vol. 15, no. 1, article 63, 2015. View at Publisher · View at Google Scholar · View at Scopus
  57. I. Popovich, B. Windsor, V. Jordan, M. Showell, B. Shea, and C. M. Farquhar, “Methodological quality of systematic reviews in subfertility: a comparison of two different approaches,” PLoS ONE, vol. 7, no. 12, Article ID e50403, 2012. View at Publisher · View at Google Scholar · View at Scopus
  58. X. Qi, M. Yang, W. Ren et al., “Find duplicates among the PubMed, EMBASE, and cochrane library databases in systematic review,” PLoS ONE, vol. 8, no. 8, Article ID e71838, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Loebel, J. Xu, J. Hsu, J. Cucchiaro, and A. Pikalov, “The development of lurasidone for bipolar depression,” Annals of the New York Academy of Sciences, vol. 1358, no. 1, pp. 95–104, 2015. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Citrome, “A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach,” CNS Drugs, vol. 27, no. 11, pp. 879–911, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. K. N. Fountoulakis, M. Gazouli, J. Kelsoe, and H. Akiskal, “The pharmacodynamic properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder,” European Neuropsychopharmacology, vol. 25, no. 3, pp. 335–342, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. W. M. Greenberg and L. Citrome, “Pharmacokinetics and pharmacodynamics of lurasidone hydrochloride, a second-generation antipsychotic: a systematic review of the published literature,” Clinical Pharmacokinetics, vol. 56, no. 5, pp. 493–503, 2017. View at Publisher · View at Google Scholar
  63. R. S. McIntyre, D. S. Cha, M. Alsuwaidan, D. McIntosh, A. M. Powell, and J. M. Jerrell, “A review of published evidence reporting on the efficacy and pharmacology of lurasidone,” Expert Opinion on Pharmacotherapy, vol. 13, no. 11, pp. 1653–1659, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. L. Orsolini, C. Tomasetti, A. Valchera et al., “An update of safety of clinically used atypical antipsychotics,” Expert Opinion on Drug Safety, vol. 15, no. 10, pp. 1329–1347, 2016. View at Publisher · View at Google Scholar
  65. J. M. Meyer, A. D. Loebel, and E. Schweizer, “Lurasidone: a new drug in development for schizophrenia,” Expert Opinion on Investigational Drugs, vol. 18, no. 11, pp. 1715–1726, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Franklin, S. Zorowitz, A. K. Corse, A. S. Widge, and T. Deckersbach, “Lurasidone for the treatment of bipolar depression: an evidence-based review,” Neuropsychiatric Disease and Treatment, vol. 11, pp. 2143–2152, 2015. View at Publisher · View at Google Scholar · View at Scopus
  67. K. Rajagopalan, E. D. Bacci, K. W. Wyrwich, A. Pikalov, and A. Loebel, “The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial,” International Journal of Bipolar Disorders, vol. 4, no. 1, p. 1, 2016. View at Google Scholar
  68. Y.-Y. Chiu, L. Ereshefsky, S. H. Preskorn, N. Poola, and A. Loebel, “Lurasidone drug-drug interaction studies: a comprehensive review,” Drug Metabolism and Drug Interactions, vol. 29, no. 3, pp. 191–202, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. W. K. Kennedy, M. W. Jann, and E. C. Kutscher, “Clinically significant drug interactions with atypical antipsychotics,” CNS Drugs, vol. 27, no. 12, pp. 1021–1048, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. J. De Leon, V. Santoro, C. D'Arrigo, and E. Spina, “Interactions between antiepileptics and second-generation antipsychotics,” Expert Opinion on Drug Metabolism and Toxicology, vol. 8, no. 3, pp. 311–334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Fala, “Latuda (Lurasidone HCl) Receives 2 New Indications for Use in Bipolar Depression as Monotherapy and as Adjunctive Therapy with Lithium or Valproate,” American Health & Drug Benefits.
  72. “Sunivon®. Latuda® (lurasidone HCl) Prescribing Information,” 2016, https://www.google.it/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&uact=8&ved=0ahUKEwjc4oCE3e7PAhVGshQKHXiQBwQQFggoMAA&url=http%3A%2F%2Fwww.latuda.com%2FLatudaPrescribingInformation.pdf&usg=AFQjCNH01TNyYsBUFNHXmkeYUltV0h9_mA.
  73. A. Loebel and L. Citrome, “Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression,” Psychiatrist, vol. 39, no. 5, pp. 237–241, 2015. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Horisawa, T. Ishibashi, H. Nishikawa et al., “The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone,” Behavioural Brain Research, vol. 220, no. 1, pp. 83–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. T. Ishibashi, T. Horisawa, K. Tokuda et al., “Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 171–181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. K. N. Fountoulakis, J. R. Kelsoe, and H. Akiskal, “Receptor targets for antidepressant therapy in bipolar disorder: an overview,” Journal of Affective Disorders, vol. 138, no. 3, pp. 222–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. J. K. Zubieta and N. E. Alessi, “Is there a role of serotonin in the disruptive behavior disorders? A literature review,” Journal of Child and Adolescent Psychopharmacology, vol. 3, no. 1, pp. 11–35, 1993. View at Publisher · View at Google Scholar
  78. L. N. Yatham, J. M. Goldstein, E. Vieta et al., “Atypical antipsychotics in bipolar depression: potential mechanisms of action,” Journal of Clinical Psychiatry, vol. 66, supplement 5, pp. 40–48, 2005. View at Google Scholar · View at Scopus
  79. P. Blier and N. M. Ward, “Is there a role for 5-HT1A agonists in the treatment of depression?” Biological Psychiatry, vol. 53, no. 3, pp. 193–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Brugue and E. Vieta, “Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 1, pp. 275–282, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. L. N. Cates, A. J. Roberts, S. Huitron-Resendiz, and P. B. Hedlund, “Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype,” Neuropharmacology, vol. 70, pp. 211–217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Huang, M. Horiguchi, A. R. Felix, and H. Y. Meltzer, “5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux,” NeuroReport, vol. 23, no. 7, pp. 436–440, 2012. View at Publisher · View at Google Scholar · View at Scopus
  83. O. Mnie-Filali, L. Lambas-Señas, H. Scarna, and N. Haddjeri, “Therapeutic potential of 5-HT7 receptors in mood disorders,” Current Drug Targets, vol. 10, no. 11, pp. 1109–1117, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Y. Meltzer, “The role of serotonin in antipsychotic drug action,” Neuropsychopharmacology, vol. 21, no. 2, pp. 106S–115S, 1999. View at Publisher · View at Google Scholar · View at Scopus
  85. R. J. Roberts, K. K. Lohano, and R. S. El-Mallakh, “Antipsychotics as antidepressants,” Asia-Pacific Psychiatry, vol. 8, no. 3, pp. 179–188, 2015. View at Publisher · View at Google Scholar
  86. D. K. Shayegan and S. M. Stahl, “Atypical antipsychotics: matching receptor profile to individual patient's clinical profile,” CNS Spectrums, vol. 9, no. 10, pp. 6–14, 2004. View at Google Scholar · View at Scopus
  87. N. A. Keks, J. Hope, and D. Castle, “Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?” Australasian Psychiatry, vol. 24, no. 3, pp. 289–291, 2016. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Fang, H. Sun, Z. Wang, M. Ren, J. R. Calabrese, and K. Gao, “Antipsychotic drug-induced somnolence: incidence, mechanisms, and management,” CNS Drugs, vol. 30, no. 9, pp. 845–867, 2016. View at Publisher · View at Google Scholar · View at Scopus
  89. J. De Fruyt, E. Deschepper, K. Audenaert et al., “Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis,” Journal of Psychopharmacology, vol. 26, no. 5, pp. 603–617, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Citrome, A. Pikalov, M. Tocco et al., Sunovion Pharmaceuticals Europe Ltd. to Present New Data on LATUDA®? (lurasidone) at the 23rd European Congress of Psychiatry.
  91. M. Sajatovic, D. Ng-Mak, C. T. Solem, F. Lin, K. Rajagopalan, and A. Loebel, “Dosing patterns and medication adherence in bipolar disorder patients treated with lurasidone: a US retrospective claims database analysis,” Therapeutic Advances in Psychopharmacology, vol. 6, no. 6, pp. 355–368, 2016. View at Publisher · View at Google Scholar
  92. M. G. Carta, M. F. Moro, A. E. Nardi, and J. R. Calabrese, “Potential use of lurasidone for the treatment of bipolar psychosis,” Expert Opinion on Investigational Drugs, vol. 24, no. 4, pp. 575–584, 2015. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Loebel, C. Siu, K. Rajagopalan, A. Pikalov, J. Cucchiaro, and T. A. Ketter, “Recovery in bipolar depression: post-hoc analysis of a placebo-controlled lurasidone trial followed by a long-term continuation study,” Journal of Affective Disorders, vol. 186, pp. 376–382, 2015. View at Publisher · View at Google Scholar · View at Scopus
  94. R. S. McIntyre, J. Cucchiaro, A. Pikalov, H. Kroger, and A. Loebel, “Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: post hoc analysis of a randomized placebo-controlled trial,” The Journal of Clinical Psychiatry, vol. 76, no. 4, pp. 398–405, 2015. View at Publisher · View at Google Scholar · View at Scopus
  95. J. Lataster, J. Van Os, L. De Haan et al., “Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone, or olanzapine: an experience sampling study,” Journal of Clinical Psychiatry, vol. 72, no. 10, pp. 1397–1404, 2011. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Nierenberg, J. Tsai, Y. Mao, A. Pikalov, T. Suppes, and A. Loebel, “Efficacy of lurasidone in major depression with mixed features: pattern of improvement in depressive and manic symptoms,” European Psychiatry, vol. 33, p. S423, 2016. View at Google Scholar
  97. T. Suppes, R. Silva, J. Cucchiaro et al., “Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study,” American Journal of Psychiatry, vol. 173, no. 4, pp. 400–407, 2016. View at Publisher · View at Google Scholar · View at Scopus
  98. J. Hu, R. Mansur, and R. S. McIntyre, “Mixed specifier for bipolar mania and depression: highlights of DSM-5 changes and implications for diagnosis and treatment in primary care,” The Primary Care Companion for CNS Disorders, vol. 16, no. 2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Fornaro, D. De Berardis, F. Iasevoli et al., “Corrigendum to ‘Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and “therapeutic sensation seeking” in response towards subjective intolerance to pain’ [J. Affect. Disord. 151 (2) (November 2013), 596–604],” Journal of Affective Disorders, vol. 170, p. 22, 2015. View at Publisher · View at Google Scholar
  100. M. Fornaro, D. De Berardis, F. Iasevoli et al., “Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: relationship with cyclothymic temperament and ‘therapeutic sensation seeking’ in response towards subjective intolerance to pain,” Journal of Affective Disorders, vol. 151, no. 2, pp. 596–604, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. L. N. Yatham, S. Mackala, J. Basivireddy et al., “Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study,” The Lancet Psychiatry, vol. 4, no. 3, pp. 208–217, 2017. View at Publisher · View at Google Scholar
  102. K. E. Burdick, T. A. Ketter, J. F. Goldberg, and J. R. Calabrese, “Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design,” Journal of Clinical Psychiatry, vol. 76, no. 3, pp. e342–e350, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. C. T. Sudhir Kumar and S. Frangou, “Clinical implications of cognitive function in bipolar disorder,” Therapeutic Advances in Chronic Disease, vol. 1, no. 3, pp. 85–93, 2010. View at Publisher · View at Google Scholar · View at Scopus
  104. M. A. Frye, M. L. Prieto, W. V. Bobo et al., “Current landscape, unmet needs, and future directions for treatment of bipolar depression,” Journal of Affective Disorders, vol. 169, no. 1, pp. S17–S23, 2014. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Pikalov, J. Tsai, Y. Mao, R. Silva, J. Cucchiaro, and A. Loebel, “Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment,” International Journal of Bipolar Disorders, vol. 5, no. 1, article 9, 2017. View at Publisher · View at Google Scholar
  106. American Psychiatric Association Publishing, Diagnostic and Statistical Manual of Mental Disorders (DSM-5®), American Psychiatric Association Publishing, 2013.
  107. G. M. Goodwin, P. M. Haddad, I. N. Ferrier et al., “Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology,” Journal of Psychopharmacology, vol. 30, no. 6, pp. 495–553, 2016. View at Publisher · View at Google Scholar · View at Scopus